Pandemic-response adenoviral vector and RNA vaccine manufacturing.

Kis, Zoltán; Tak, Kyungjae; Ibrahim, Dauda; Papathanasiou, Maria M; Chachuat, Benoît; Shah, Nilay; Kontoravdi, Cleo

Kis, Zoltán; Tak, Kyungjae; Ibrahim, Dauda; Papathanasiou, Maria M; Chachuat, Benoît; Shah, Nilay; Kontoravdi, Cleo.

Kis Z; The Sargent Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK. z.kis@sheffield.ac.uk.
Tak K; Department of Chemical and Biological Engineering, The University of Sheffield, Mappin Street, Sheffield, S1 3JD, UK. z.kis@sheffield.ac.uk.
Ibrahim D; The Sargent Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK.
Papathanasiou MM; The Sargent Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK.
Chachuat B; The Sargent Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK.
Shah N; The Sargent Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK.
Kontoravdi C; The Sargent Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK.

NPJ Vaccines ; 7(1): 29, 2022 Mar 02.

Article in English | MEDLINE | ID: covidwho-1721524

ABSTRACT

ABSTRACT

Rapid global COVID-19 pandemic response by mass vaccination is currently limited by the rate of vaccine manufacturing. This study presents a techno-economic feasibility assessment and comparison of three vaccine production platform technologies deployed during the COVID-19 pandemic (1) adenovirus-vectored (AVV) vaccines, (2) messenger RNA (mRNA) vaccines, and (3) the newer self-amplifying RNA (saRNA) vaccines. Besides assessing the baseline performance of the production process, impact of key design and operational uncertainties on the productivity and cost performance of these vaccine platforms is quantified using variance-based global sensitivity analysis. Cost and resource requirement projections are computed for manufacturing multi-billion vaccine doses for covering the current global demand shortage and for providing annual booster immunisations. The model-based assessment provides key insights to policymakers and vaccine manufacturers for risk analysis, asset utilisation, directions for future technology improvements and future epidemic/pandemic preparedness, given the disease-agnostic nature of these vaccine production platforms.

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Journal: NPJ Vaccines Year: 2022 Document Type: Article Affiliation country: S41541-022-00447-3

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google